Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This trial studies how well fluciclovine 18F PET/CT imaging works in assessing hormone-naive
men with prostate cancer that has spread to the bone. Fluciclovine 18F is a radioactive drug
used to measure tumor growth. PET/CT uses x-rays to take pictures inside the body. Comparing
results of fluciclovine 18F PET/CT imaging may help doctors predict a patient's response to
treatment and help plan the best treatment.